Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice

Psychopharmacology

Volumn 168, Issue 4, 2003, Pages 417-425

  Raud, Sirli ^a   Rünkorg, Kertu ^a   Veraksitš, Alar ^a   Reimets, Ain ^a   Nelovkov, Aleksei ^a   Abramov, Urho ^a   Matsui, Toshimitsu ^b   Bourin, Michel ^c   Volke, Vallo ^a   Kõks, Sulev ^a   Vasar, Eero ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Anxiety; Benzodiazepine receptors; Cholecystokinin; Cholecystokinin2 receptors; Diazepam; Elevated plus maze; Exploratory behaviour; GABA; Heterozygous; Homozygous; Motor co ordination; Rotarod test; Targeted mutagenesis; Wild type

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR; CHOLECYSTOKININ RECEPTOR; DIAZEPAM; FLUNITRAZEPAM; FLUNITRAZEPAM H 3; RADIOLIGAND; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; GENE MUTATION; GENE TARGETING; LOCOMOTION; MAZE TEST; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; BRAIN CORTEX; CEREBELLUM; CHEMISTRY; EXPLORATORY BEHAVIOR; GENETICS; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; MUTATION; PHYSIOLOGY; RADIOASSAY; ROTAROD TEST;

ANIMALS; ANXIETY; CEREBELLUM; CEREBRAL CORTEX; DIAZEPAM; EXPLORATORY BEHAVIOR; FEMALE; FLUNITRAZEPAM; GENE TARGETING; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; MUTATION; RADIOLIGAND ASSAY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, GABA-A; ROTAROD PERFORMANCE TEST; TRITIUM;

EID: 0042739174     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1453-7     Document Type: Article

References (49)

1. Bradford MM (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
2. Bradwejn J, de Montigny C (1984) Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature 312:363-364
3. Bradwejn J, Vasar E (1995) Cholecystokinin and panic disorder. In: Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. R.B. Landes, Austin, pp 73-86
4. Cope DW, Maccaferri G, Marton LF, Roberts JD, Cobden PM, Somogyi P (2002) Cholecystokinin-immunopositive basket and Schaffer collateral-associated interneurones target different domains of pyramidal cells in the CA1 area of the rat hippocampus. Neuroscience 109:63-80
5. Crawley JN (1992) Subtype selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 12:3380-3391
6. 2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine. Neurosci Lett 306:41-44
7. 2 receptor-deficient mice. Neuropsychopharmacol 25:690-698
8. B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 121:109-117
9. Fekete M, Lengyel A, Hegedüs B, Penke B, Zarandy M, Toth GK,Telegdy G (1984) Further analysis of the effects of cholecystokinin octapeptide on avoidance behavior in rats. Eur J Pharmacol 98:79-91
10. B receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices. J Neurochem 73:1973-1981
11. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego
12. Griebel G (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders. Pharmacol Ther 1:1-61
13. Harro J (1993) Studies on the brain cholecystokinin receptors and behaviour (dissertation). Acta Universitatis Upsaliensis, v. 421. Uppsala University Press, Uppsala, pp 42
14. B receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 193:379-381
15. Harro J, Vasar E (1991b) Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour. Neurosci Biobehav Rev 15:473-477
16. Harro J, Kiivet RA, Lang A, Vasar E (1990) Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 39:63-71
17. Harro J, Vasar E, Bradwejn (1993) Cholecystokinin in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249
18. Hendry SHC, Jones EG, De Felipe J, Schmechel D, Brandon C, Emcon PC (1984) Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci USA 81:6526-6530
19. Homanics GE, Quinlan JJ, Firestone LL (1999) Pharmacological and behavioural responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol Biochem Behav 63:21-26
20. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a new class of selective cholecystokinin type B antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
21. Johnston AL, File SE (1991) Sex differences in animal tests of anxiety. Physiol Behav 49:245-250
22. Kõks S, Vasar E, Soosaar A, Lang A, Volke, Võikar V, Bourin M, Männistö PT (1997) Relation of exploratory of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol 7:289-294
23. Kõks S. Männistö PT, Bourin M, Shlik J, Vasar V, Vasar E (2000) Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatr Neurosci 25:33-42
24. 2 receptor deficient mice display altered function of brain dopaminergic system. Psychopharmacology 158:198-204
25. 2 receptors. Neuropeptides 37:25-29
26. Korpi ER, Koikkalainen P, Vekovischeva OY, Makela R, Kleinz R, Uusi-Oukari M, Wisden W (1999) Cerebellar granule-cell-specific GABAA receptors attenuate benzodiazepine-induced ataxia: evidence from alpha 6-subunit-deficient mice. Eur J Neurosci 11:233-240
27. Kosaka T, Kosaka K, Tateishi K, Hamaoka Y, Yanaihara N, Wu JY, Hama K (1985) GABAergic neurons containing CCK-8-like and/or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J Comp Neurol 239:420-430
28. Lister RG (1987) The use of plus-maze to measure anxiety in mouse. Psychopharmacology 92:180-185
29. Mason C, Sotelo C (eds) (1997) The cerebellum: a model for construction of a cortex. Perspect Dev Neurobiol 5:1-95
30. + conductance in hippocampal interneurons. J Neurosci 13:4994-5003
31. Möhler H, Fritschy JM, Rudolph U (2002) A new benzodiazepine pharmacology. J Pharmacol Exp Ther 200:2-8
32. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T, Noda T (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 93:11825-11830
33. Nobel F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, Roques BP (1999) International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51:745-781
34. A-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390-396
35. 2 agonists. Eur Neuropsychopharmacol 2:193-195
36. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in rat. J Neurosci Meth 14:149-167
37. 3H] gamma-aminobutyric acid release in slices from various brain areas. Eur J Pharmacol 1993 250:423-430
38. 2 receptor in mice results in an upregulation of the endogenous opioid system. J Neurosci 22:2005-2011
39. B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19:75-78
40. Rägo L, Kiivet RA, Harro J, Põld (1988) Behavioral differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex. Naunyn-Schmiedeberg's Arch Pharmacol 337:675-678
41. Rasmussen K, Helton DR, Berger J, Scearce E (1993) The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. Neuroreport 5:154-156
42. Rodgers RJ, Cao B-J, Dalvi A, Holmes A (1997) Animal models of anxiety: an ethological perspective. Brazil J Med Biol Res 30:289-304
43. Sebret A, Léna I, Crété D, Matsui T, Roques BP, Daugé V (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19:7230-7237
44. Shlik J, Vasar E, Bradwejn J (1997) Cholecystokinin and psychiatric disorders: role in aetiology and potential of receptor antagonists in therapy. CNS Drugs 8:134-152
45. Singh L, Field MJ, Vass CA, Hughes J, Woodruff GN (1992) The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Br J Pharmacol 105:8-10
46. Somogyi P, Hodgson AJ, Smith AD, Nunzi MG, Gorio A, Wu J-Y (1984) Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material. J Neurosci 4:2590-2603
47. B receptor knockout mice: gender related behavioural differences. Eur Neuropsychopharmacol 10:S69
48. 2 receptors display reduced anxiety in the plus-maze. Eur Psychiatr Suppl 1:50
49. Woodruff GN, Hughes J (1991) Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 31:469-501